

## Overview

### Useful For

Identifying variants within the *ARSB* gene

Confirmation of a diagnosis of mucopolysaccharidosis type VI

Carrier testing, when there is a family history of mucopolysaccharidosis type VI, but disease-causing variants have not been previously identified

### Genetics Test Information

Testing includes full gene sequencing of the *ARSB* gene.

### Reflex Tests

Test ID	Reporting Name	Available Separately	Always Performed
FIBR	Fibroblast Culture	Yes	No
CRYOB	Cryopreserve for Biochem Studies	No	No

### Testing Algorithm

If a skin biopsy is received, fibroblast culture and cryopreservation for biochemical studies will be performed at an additional charge.

See [Lysosomal Storage Disorders Diagnostic Algorithm, Part 1](#) in Special Instructions.

### Special Instructions

- [Molecular Genetics: Biochemical Disorders Patient Information](#)
- [Informed Consent for Genetic Testing](#)
- [Blood Spot Collection Card-Spanish Instructions](#)
- [Blood Spot Collection Card-Chinese Instructions](#)
- [Informed Consent for Genetic Testing \(Spanish\)](#)
- [Lysosomal Storage Disorders Diagnostic Algorithm, Part 1](#)
- [Blood Spot Collection Instructions](#)

### Method Name

Polymerase Chain Reaction (PCR) followed by DNA Sequencing

### NY State Available

Yes

## Specimen

### Specimen Type

---

Varies

**Advisory Information**

First-tier testing for mucopolysaccharidosis type VI is available. Order MPSQU / Mucopolysaccharides Quantitative, Random, Urine.

**Shipping Instructions**

Specimen preferred to arrive within 96 hours of collection.

**Specimen Required**

**Patient Preparation:** A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

**Submit only 1 of the following specimens:****Preferred:**

**Specimen Type:** Whole blood

**Container/Tube:**

**Preferred:** Lavender top (EDTA) or yellow top (ACD)

**Acceptable:** Any anticoagulant

**Specimen Volume:** 3 mL

**Collection Instructions:**

1. Invert several times to mix blood.
2. Send specimen in original tube.

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Specimen Type:** Cultured fibroblasts

**Container/Tube:** T-75 or T-25 flask

**Specimen Volume:** 1 Full T-75 flask or 2 full T-25 flasks

**Specimen Stability Information:** Ambient (preferred)/Refrigerated <24 hours

**Specimen Type:** Skin biopsy

**Supplies:** Fibroblast Biopsy Transport Media (T115)

**Container/Tube:** Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.

**Specimen Volume:** 4-mm punch

---

**Specimen Stability Information:** Refrigerated (preferred)/Ambient

**Acceptable:**

**Specimen Type:** Blood spot

**Supplies:** Card - Blood Spot Collection (Filter Paper) (T493)

**Container/Tube:**

**Preferred:** Collection card (Whatman Protein Saver 903 Paper)

**Acceptable:** Ahlstrom 226 filter paper, or Blood Spot Collection Card

**Specimen Volume:** 2 to 5 Blood spots on collection card

**Collection Instructions:**

1. An alternative blood collection option for a patient older than 1 year of age is finger stick.
2. Let blood dry on the filter paper at ambient temperature in a horizontal position for 3 hours.
3. Do not expose specimen to heat or direct sunlight.
4. Do not stack wet specimens.
5. Keep specimen dry

**Specimen Stability Information:** Ambient (preferred)/Refrigerated

**Additional Information:**

1. For collection instructions, see [Blood Spot Collection Instructions](#) in Special Instructions.
2. For collection instructions in Spanish, see [Blood Spot Collection Card-Spanish Instructions](#) (T777) in Special Instructions.
3. For collection instructions in Chinese, see [Blood Spot Collection Card-Chinese Instructions](#) (T800) in Special Instructions.

**Forms**

**[1. New York Clients-Informed consent is required.](#)** Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

-[Informed Consent for Genetic Testing](#) (T576)

-[Informed Consent for Genetic Testing-Spanish](#) (T826)

2. [Molecular Genetics: Biochemical Disorders Patient Information](#)(T527) in Special Instructions

3. If not ordering electronically, complete, print, and send an [Inborn Errors of Metabolism Test Request](#) (T798) with the specimen.

## Specimen Minimum Volume

Blood: 1 mL

Blood Spots: 5 punches, 3-mm diameter

## Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Varies		

## Clinical and Interpretive

### Clinical Information

Mucopolysaccharidosis type VI (MPS-VI), also known as Maroteaux-Lamy syndrome, is an autosomal recessive condition that is caused by variants in the *ARSB* gene and is characterized by reduced or absent activity of the arylsulfatase B enzyme. This test screens for variants in all 8 exons of the *ARSB* gene.

The clinical features and severity of symptoms of Maroteaux-Lamy are widely variable. Typically it is characterized by short stature, dysostosis multiplex, facial dysmorphism, stiff joints, hepatosplenomegaly, corneal clouding, cardiac defects, and usually normal intelligence. With a rapidly progressing form of MPS-VI, onset occurs before 2 to 3 years of age with death typically occurring in the second to third decade. With a slowly progressing form of MPS-VI, a diagnosis usually occurs after 5 years of age but may not occur until the second or third decade.

The recommended first-tier test for MPS-VI is measurement of mucopolysaccharides in urine (MPSQU / Mucopolysaccharides Quantitative, Random, Urine) or enzyme testing for arylsulfatase B.

### Reference Values

An interpretive report will be provided.

### Interpretation

All detected alterations are evaluated according to American College of Medical Genetics and Genomics (ACMG) recommendations.<sup>(1)</sup> Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.

### Cautions

A small percentage of individuals who are carriers or have a diagnosis of mucopolysaccharidosis type VI (MPS-VI) may have a variant that is not identified by this method (eg, large genomic deletions, promoter alterations). The absence of a variant, therefore, does not eliminate the possibility of positive carrier status or the diagnosis of MPS-VI. The preferred approach to carrier testing is to first document the presence of an *ARSB* gene variant in an affected family member.

In some cases, DNA alterations of undetermined significance may be identified.

Rare alterations exist that could lead to false-negative or false-positive results. If results obtained do not match the clinical findings, additional testing should be considered.

---

Test results should be interpreted in the context of clinical findings, family history, and other laboratory data. Errors in the interpretation of results may occur if information given is inaccurate or incomplete.

### Clinical Reference

1. Richards S, Aziz N, Bale S, et al: Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015 May;17(5):405-424
2. Litjens T, Hopwood JJ: Mucopolysaccharidosis type VI: Structural and clinical implications of mutations in N-acetylgalactosamine-4-sulfatase. *Hum Mutat.* 2001;18(4):282-295
3. Valayannopoulos V, Nicely H, Harmatz P, Turbeville S: Mucopolysaccharidosis VI. *Orphanet J Rare Dis.* 2010;5:5

### Performance

#### Method Description

Bidirectional sequence analysis is used to test for the presence of a variant in all coding regions and intron/exon boundaries of the *ARSB* gene. (Unpublished Mayo method)

#### PDF Report

No

#### Day(s) and Time(s) Test Performed

Performed weekly; Varies

#### Analytic Time

14 days

#### Maximum Laboratory Time

20 days

#### Specimen Retention Time

Whole Blood: 2 weeks (if available); Extracted DNA: 3 months

#### Performing Laboratory Location

Rochester

### Fees and Codes

#### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact [Customer Service](#).

#### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

#### CPT Code Information

81479-Unlisted molecular pathology procedure code

---

88233-Tissue culture, skin, or solid tissue biopsy (if appropriate)

88240-Cryopreservation (if appropriate)

**LOINC® Information**

Test ID	Test Order Name	Order LOINC Value
MPS6Z	MPSVI, Full Gene Analysis	94210-2

Result ID	Test Result Name	Result LOINC Value
54013	Result Summary	50397-9
54014	Result	82939-0
54015	Interpretation	69047-9
54016	Additional Information	48767-8
54017	Specimen	31208-2
54018	Source	31208-2
54019	Released By	18771-6